March 28, 2018 / 11:25 AM / 5 months ago

BRIEF-Abide And Celgene Enter Worldwide License Agreement For ABX-1772

March 28 (Reuters) - Celgene Corp:

* ABIDE AND CELGENE ENTER WORLDWIDE LICENSE AGREEMENT FOR ABX-1772

* ‍ABIDE THERAPEUTICS SAYS GRANTED CELGENE AN EXCLUSIVE WORLDWIDE LICENSE FOR ABX-1772, A PRECLINICAL DRUG CANDIDATE DISCOVERED BY ABIDE​

* ‍ABIDE THERAPEUTICS SAYS ABIDE RECEIVED UNDISCLOSED PAYMENT AND WILL BE ENTITLED TO CERTAIN MILESTONE PAYMENTS AND ROYALTIES ON COMMERCIAL SALES​

* ‍ABIDE THERAPEUTICS SAYS ABIDE HAS REGAINED EX-US RIGHTS TO ABX-1431 FROM CELGENE​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below